Pantera® Lux Paclitaxel Releasing Balloon is launched during the EuroPCR meeting

BIOTRONIK's first drug eluting balloon is indicated for the treatment of coronary in-stent restenosis

(PresseBox) ( Buelach, Switzerland, )
BIOTRONIK AG today announced the international launch for its new Pantera Lux Paclitaxel Releasing Balloon for the treatment of coronary instent restenosis.

The Pantera Lux is a balloon catheter coated with a matrix of proven paclitaxel and biocompatible carrier for treating coronary lesions that have occluded after the implantation of a stent. This treatment option allows for the application of an antiproliferative drug to achieve a sustained reopening of the renarrowed artery without leaving another stent or permanent device behind.

"Drug eluting stents are the standard treatment for instent restenosis, but carry with them limitations such as late stent thrombosis, prolonged dual antiplatelet therapy and the problem of reintervention if restenosis occurs again," said Ron Waksman, MD, Associate Director from the Washington Heart Center, USA. "In the future, drug eluting balloons can be used in a subset of lesions where drug eluting stents do not perform well, such as in bifurcated lesions and torturous or small vessels where scaffolding can be an obstruction."

The BIOTRONIK drug eluting balloon (DEB) makes use of paclitaxel as an antiproliferative treatment due to its rapid uptake and prolonged retention. The absorption properties of the drug are further enhanced with the addition of an excipient, called butyryltrihexyl citrate (BTHC), which acts as an agent to keep the paclitaxel microcrystalline, a form that shows even faster uptake by the vessel wall. BTHC is a safe and well characterized compound used in other bloodrelated medical devices.

"The methodology in which the drug is maintained on the balloon surface will become a key factor in how effective the device is," commented Prof. Christoph Hehrlein, MD, Director of Cardiac Catheterization at University of Freiburg, Germany and Principal Investigator of the PEPPER Study, a 80patient singlearmed, international study to assess the safety and efficacy of the Pantera Lux. "It's a delicate balance of an adequate adherence of the drug to the balloon while still achieving the proper drug release at the lesion site. With the Lux device, the flexible balloon materials give it good trackability while sheltering the drug within the folds of the balloon."

The Pantera Lux balloon was designed with the underlying Pantera balloon technology as the delivery device. BIOTRONIK's Pantera balloon was released in 2008 and has developed in the market as one of the top performing balloon devices for treating coronary disease.

"We've done extensive studies in animal models to determine the most optimal combination of drug, excipient and dosage. From these studies we know that with a short application of 30 seconds, the drug can be measured in the tissue for up to 7 days," said Vice President of Sales & Marketing, Alain Aimonetti. "We are confident that the Pantera Lux is a solid alternative for instent restenosis and possibly for other indications that physicians struggle with where the placement of a permanent device is not optimal."

BIOTRONIK plans to release a drug eluting balloon on a 0.018'' OTW platform for the treatment of superficial femoral artery disease later this year.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to